Do GLP-1 Drugs Change How the Brain Responds to Food and Reward Cues?
Limited fMRI evidence tentatively suggests GLP-1 receptor agonists may reduce brain reactivity to food cues in reward regions, but studies are small, inconsistent, and effects may diminish over time.
Quick Facts
What This Study Found
Only 11 fMRI studies exist on GLP-1 RA effects on brain reward responses. Limited evidence suggests acute administration may reduce food cue reactivity in appetite and reward brain regions, but effects appear inconsistent and may attenuate with chronic treatment.
Key Numbers
How They Did This
Systematic review of 1,209 records from comprehensive literature search, with 11 studies meeting eligibility criteria for analysis of fMRI-measured brain responses to reward cues during GLP-1 RA treatment.
Why This Research Matters
Understanding how GLP-1 drugs affect brain reward circuits is crucial for explaining their weight loss effects and potential for treating substance use disorders like alcohol addiction.
The Bigger Picture
The potential for GLP-1 drugs to treat addiction by modulating reward circuits is generating enormous interest. This review reveals how little we actually know about these brain mechanisms and highlights the urgent need for larger, better-designed neuroimaging studies.
What This Study Doesn't Tell Us
Very few eligible studies (11). Small sample sizes throughout. Heterogeneous medications, doses, and protocols. Almost no data on non-food reward cues. No standardized control conditions.
Questions This Raises
- ?Do GLP-1 drugs reduce brain reward responses to alcohol and other addictive substances?
- ?Why might the brain reward-dampening effects of GLP-1 drugs diminish with chronic use?
- ?How do individual differences (obesity, addiction history) affect brain responses to GLP-1 drugs?
Trust & Context
- Key Stat:
- Only 11 studies Despite massive clinical interest, very few neuroimaging studies have examined how GLP-1 drugs affect brain reward circuits
- Evidence Grade:
- Systematic review finding a very limited evidence base. The field is in its infancy, with most studies underpowered and methodologically heterogeneous.
- Study Age:
- Published in 2025, mapping the current gaps in understanding GLP-1 brain mechanisms.
- Original Title:
- Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review.
- Published In:
- bioRxiv : the preprint server for biology (2026)
- Authors:
- Dang, Vincent, Sambuco, Nicola, Yammine, Luba(4), Versace, Francesco
- Database ID:
- RPEP-15075
Evidence Hierarchy
Frequently Asked Questions
Can Ozempic or Wegovy help with food addiction?
Limited brain imaging evidence suggests GLP-1 drugs may temporarily reduce how strongly the brain responds to food cues. However, the evidence is still very sparse and inconsistent, so it is too early to draw firm conclusions.
Could GLP-1 drugs treat other addictions like alcoholism?
Only one brain imaging study has examined GLP-1 drugs and alcohol cues. While there is theoretical interest, much more research is needed before GLP-1 drugs could be considered for addiction treatment.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15075APA
Dang, Vincent; Sambuco, Nicola; Yammine, Luba; Versace, Francesco. (2026). Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review.. bioRxiv : the preprint server for biology. https://doi.org/10.64898/2026.01.31.702984
MLA
Dang, Vincent, et al. "Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review.." bioRxiv : the preprint server for biology, 2026. https://doi.org/10.64898/2026.01.31.702984
RethinkPeptides
RethinkPeptides Research Database. "Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-R..." RPEP-15075. Retrieved from https://rethinkpeptides.com/research/dang-2026-do-glp1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.